EUVIMEDEUVIMED entdecken
Crossref

1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D

PETTER BJORNSTAD, TAMARA S. HANNON, JUAN M. MALDONADO, KARI RANTA, KARTHIK CHANDRASEKHAR PAMIDIPATI, HIREN PATEL, BRANDON BERGMAN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1134-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von PETTER BJORNSTAD und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Tirzepatide (TZP) demonstrated improvements in glycemic control and BMI in participants with youth-onset type 2 diabetes (YT2D) in SURPASS-PEDS. TZP impact on glomerular hyperfiltration, an early disease marker affecting 24% of YT2D, was not previously assessed. This analysis examined changes in estimated glomerular filtration rate (eGFR) and hyperfiltration status with TZP treatment.

Methods

TZP vs PBO was assessed for 30 weeks in participants 10 to <18 years old with YT2D on metformin and/or basal insulin. Participants received TZP 5 mg (n=32), 10 mg (n=33) or PBO (n=34). eGFR was calculated using Zappitelli creatinine-cystatin C equation; hyperfiltration was defined as eGFR ≥126.8 mL/min/1.73 m². Change in eGFR (MMRM) and shifts in hyperfiltration status (Fisher’s exact test) were assessed.

Results

At baseline, mean age was 14.7 years old and 18% of participants exhibited hyperfiltration (mean eGFR 142 vs 104 mL/min/1.73m2 in normofiltration). TZP treatment led to a reduction in eGFR at Week 30, with greater than two-times reduction in participants with baseline hyperfiltration (Table 1). The proportion of participants with hyperfiltration decreased in pooled TZP (18.6% to 5.5%) and increased in PBO (16.1% to 21.9%, p<0.05, TZP vs PBO).

Conclusion

In the SURPASS-PEDS trial, treatment with tirzepatide was associated with a mean decrease in eGFR, primarily ascribed to attenuation of glomerular hyperfiltration.

Trial registration

ClinicalTrials.gov (NCT05260021). Disclosure P. Bjornstad: Consultant; Current; Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. T.S. Hannon: None. J.M. Maldonado: Employee; Current; Eli Lilly and Company. K. Ranta: Employee; Current; Eli Lilly and Company. K. Pamidipati: None. H. Patel: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. B. Bergman: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. Funding Eli Lilly and Company

Zitieren

APA

BJORNSTAD, P., HANNON, T. S., MALDONADO, J. M., RANTA, K., PAMIDIPATI, K. C., PATEL, H., & BERGMAN, B. (2026). 1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1134-or

Vancouver

BJORNSTAD P, HANNON TS, MALDONADO JM, RANTA K, PAMIDIPATI KC, PATEL H, et al. 1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1134-or

BibTeX
@article{BJORNSTAD2026,
  author = {BJORNSTAD, PETTER and HANNON, TAMARA S. and MALDONADO, JUAN M. and RANTA, KARI and PAMIDIPATI, KARTHIK CHANDRASEKHAR and PATEL, HIREN and BERGMAN, BRANDON},
  title = {1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1134-or}
}
Kostenlos starten →